Holen Sie sich die Stockscreener-App
2.60
19.82%
0.43
Handel nachbörslich:
2.60
Acelyrin Inc Aktie (SLRN) Neueste Nachrichten
Activist investor threatens drug maker's merger plans with L.A. biotech - The Business Journals
Activist investor threatens Peninsula drug maker's merger plans - San Francisco Business Times
Concentra Biosciences, LLC made an Unsolicited Indication of Interest to acquire Acelyrin, Inc. from a group of shareholders for approximately $310 million. - Marketscreener.com
ACELYRIN shares surge on buyout interest By Investing.com - Investing.com Nigeria
ACELYRIN shares surge on buyout interest - Investing.com
Acelyrin Receives Unsolicited Buyout Offer From Concentra Biosciences -February 21, 2025 at 04:38 am EST - Marketscreener.com
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences - TipRanks
ACELYRIN Confirms Receipt Of Unsolicited Indication Of Interest From Concentra Biosciences - Marketscreener.com
Acelyrin, Inc. Confirms Unsolicited Acquisition Proposal from Concentra Biosciences Amidst Ongoing Merger Agreement with Alumis Inc. - Nasdaq
Can This New Cash Offer Derail ACELYRIN's Planned Alumis Merger? - StockTitan
Kuehn Law Encourages HEES, SLRN, PTMN, and IPG Investors to Contact Law Firm - TradingView
SLRN stock touches 52-week low at $1.9 amid market challenges - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, AMPS, SLRN on Behalf of Shareholders - The Malaysian Reserve
SLRN stock touches 52-week low at $1.85 amid market challenges - MSN
H.C. Wainwright cuts Alumis stock target to $19, maintains Buy rating - MSN
ACELYRIN’s Merger with Alumis - Global Legal Chronicle
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report - BioCentury
Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders - The Malaysian Reserve
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - Business Wire
Alumis and Acelyrin to merge in all-stock deal - MSN
The week in pharma: action, reaction and insight – week to February 7 | Pharmaceutical | The Pharmaletter - The Pharma Letter
Alumis To Merge With Acelyrin, But Pause Lonigutamab Program - News & Insights
TYK2s to tango, TED dead? Alumis/Acelyrin merger a capital idea - BioWorld Online
SLRN Shares Experience Decline in Value - Knox Daily
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. - PrimePublishers.com
Acelyrin Inc’s (SLRN) Stock Is Harder To Predict Than You Think - Stocks Register
Alumis and ACELYRIN announce merger in all-stock deal - MSN
Alumis and Acelyrin sign merger agreement - Yahoo
Acelyrin Inc (SLRN) Stock: Navigating a Year of Volatility - The InvestChronicle
After big IPO, Peninsula biotech plots merger, big clinical trial readouts - The Business Journals
Nasdaq Neophytes Acelyrin, Alumis Merge to Tackle Immune-Mediated Diseases - BioSpace
Immune drugmakers Alumis and Acelyrin to merge - BioPharma Dive
Alumis and ACELYRIN announce all-stock merger to focus on immune diseases - World Pharmaceutical Frontiers
Alumis stock falls on merger deal with Acelyrin (SLRN:NASDAQ) - Seeking Alpha
Acelyrin to be absorbed into Alumis in all-stock merger - Fierce Biotech
Alumis and Acelyrin merge, with $737 million cash runway - The Pharma Letter
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc.SLRN - The Malaysian Reserve
Alumis and ACELYRIN announce merger in all-stock deal By Investing.com - Investing.com Nigeria
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders - The Bakersfield Californian
Alumis And Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company - TradingView
Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company -February 06, 2025 at 05:56 pm EST - Marketscreener.com
Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company - TradingView
ACELYRIN, INC. Announces Merger with Alumis Inc. - TipRanks
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders - The Bakersfield Californian
Alumis, Acelyrin to merge in all-stock transaction - TipRanks
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - The Manila Times
Alumis Inc. and ACELYRIN, Inc. Announce Definitive Merger Agreement to Advance Late-Stage Pipeline and Clinical Development - Nasdaq
Fenwick Represents ACELYRIN in Pending Merger with Alumis - Fenwick & West LLP
ACELYRIN ends key drug development agreement - MSN
Is Acelyrin Inc (SLRN) a good investment opportunity? - US Post News
ACELYRIN ends key drug development agreement By Investing.com - Investing.com UK
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):